alflutinib
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02973763)
Timeline
Indications
Mechanism of action
FLT1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- alflutinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05209256 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2022 | Henan Medical University |
| NCT03941340 | Phase 1 | Apr 13, 2019 | Allist Pharmaceuticals, Inc., Soochow University |
| NCT03787992 | Phase 3 | Apr 1, 2019 | Allist Pharmaceuticals, Inc. |
| NCT03926182 | Phase 1 | Feb 19, 2019 | Allist Pharmaceuticals, Inc. |
| NCT03452592 | Phase 2 | Apr 30, 2018 | Allist Pharmaceuticals, Inc. |
| NCT03127449 | N/A | Jun 1, 2017 | Allist Pharmaceuticals, Inc. |
| NCT02973763 | Phase 1 | Dec 1, 2016 | Allist Pharmaceuticals, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allist Pharmaceuticals, Inc. | For profit | 6 | 6 | 4 | 2016 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1